Table 3 Rates of HBV screening a by screening period
From: Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center
Characteristic | Period 1b | Period 2c | Period 3d | P valuee | |||
|---|---|---|---|---|---|---|---|
All patients | Screened patients | All patients | Screened patients | All patients | Screened patients | ||
|  | (N = 11,833) | (N = 1754) | (N = 5703) | (N = 1037) | (N = 1152) | (N = 229) | |
Age, years, mean (SD) | 54.8 (13.6) | 51.6 (15.6) | 55.1 (13.4) | 53.1 (15.2) | 56.4 (13.1) | 56.1 (14.7) | 0.0001 |
Sex, no. (%) | Â | Â | Â | Â | Â | Â | Â |
 Female | 6702 | 731 (10.9) | 3263 | 464 (14.2) 14.22 | 643 | 110 (17.1) 17.11 | <0.0001 |
 Male | 5131 | 1023 (20.0) 19.94 | 2440 | 573 (23.5) 23.48 | 509 | 119 (23.4) 23.38 | 0.0003 |
Race/ethnicity, no. (%) | Â | Â | Â | Â | Â | Â | Â |
 White | 8464 | 1269 (15.0) | 3895 | 738 (19.0) | 809 | 161 (19.9) | <0.0001 |
 Hispanic | 1441 | 218 (15.1) | 747 | 152 (20.4) | 131 | 32 (24.0) | <0.0001 |
 Black | 1301 | 143 (11.0) | 654 | 83 (12.7) | 137 | 21 (15.3) | 0.04 |
 Asian | 311 | 45 (14.5) | 158 | 23 (14.6) | 39 | 8 (19.4) | 0.23 |
 Other | 316 | 79 (25.0) | 249 | 41(16.5) | 36 | 7 (20.5) | 0.02 |
US residence, no. (%) | 11,480 | 1675 (14.6) | 5499 | 997 (18.1) | 1111 | 224 (20.0) | <0.0001 |
HBV risk factor, no. (%) | 3412 | 572 (16.8) | 1668 | 356 (21.3) | 311 | 88 (28.3) | <0.0001 |
Cancer type, no. (%) | Â | Â | Â | Â | Â | Â | <0.0001 |
 Solid tumorf | 9521 | 326 (3.4) | 4602 | 208 (4.5) | 908 | 47 (5.2) | <0.0001 |
 Hematologic malignancy | 2312 | 1428 (61.8) | 1101 | 829 (75.3) | 244 | 182 (74.6) | <0.0001 |
Chemotherapy | Â | Â | Â | Â | Â | Â | Â |
Type, n (%) | |||||||
 Rituximab | 1244 | 785 (63.1) | 606 | 481 (79.4) | 127 | 94 (74.0) | <0.0001 |
 Non-rituximab | 10,589 | 969 (9.4) | 5097 | 556 (10.9) | 1025 | 135 (13.2) | <0.0001 |